Document is current
Any future updates will be listed below
-
Authors
Zhang, Feng
Zhang, Sun-Han
Liu, Teng
Xie, Guang-Su
Deng, Shi-Hua
Zhang, Ting
Wang, Xiao-Bian
Yang, Yue-Yan
Chen, Zi-Xin
Wu, Dong-Ming
Xu, Ying
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82273574)
National Natural Science Foundation of China (82273433)
National Natural Science Foundation of China (82203157)
Foundation of Sichuan Medical Association (S23013, Q21004, S20011)
Chengdu Medical College United Chengdu Seventh People's Hospital Open Subject (2022LHTD-01, 2022LHJYZD-01)
Chengdu Medical College United the First People's Hospital of Ziyang Open Subject (2022LHZY04)
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 20 February 2025
First Online: 7 March 2025
Declarations
:
: The animal study protocol was reviewed and approved by the Animal Policy and Welfare Committee of Chengdu Medical College (CMC-IACUC-2021024; Title: Precision Intervention Strategies for Multiple Diseases with Novel Programmed Cell Death as a Pathogenetic Mechanism; Date of approval: December 31, 2021). The manuscript adhered to the ARRIVE guidelines for the reporting of animal experiments. All animal experiments were carefully performed to avoid animal suffering. The human-derived BEAS-2B has been commercialized and is available for legal purchase under Patent US4885238.
: Not applicable.
: The authors have declared that no competing interest exists.
